17-beta-hydroxy-7 alpha-methyl-androst-5-en-3-one
synthetic anti-progestational steroid; with anti-uterotrophic and gonadotropin-inhibiting activity; structure
Also Known As:
17 beta-hydroxy-7 alpha-methylandrost-5-en-3-one; 17-beta-hydroxy-7-alpha-methyl-5-androstene-3-one; RMI 12,936; RMI 12936; RMI-12936; androst-5-en-3-one, 17-hydroxy-7-methyl-, (7 alpha,17 beta)-
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Hypertrophy
09/01/1976
- " RMI 12,936 caused luteal hypertrophy in pregnant, but not pregnant hysterectomized, rats. " 09/01/1976
- " Similar hypertrophy followed administration to pseudopregnant, immature gonadotrophin-treated, and immature hysterectomized and gonadotrophin-treated rats, but the ovarian sensitivity to gonadotrophins was reduced or unchanged, suggesting that the ovarian hypertrophy is due to a direct ovarian action of RMI 12,936. " 06/01/1975
- " On Day 8 of pregnancy, RMI 12,936 resulted in significant ovarian hypertrophy, apparent within 48 hr, possibly due to a luteotrophic stimulus of placental origin. "
|
2. | Wounds and Injuries (Trauma)
|
|
Related Drugs and Biologics